NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.
US-based cancer immunotherapy developer NexImmune raised $110m in an upsized initial public offering on the Nasdaq Global Market on Thursday, providing exits to pharmaceutical firms Amgen and Pfizer.
The company issued nearly 6.5 million shares priced at $17, the top of its range, and shares closed at $25.33 on the first day of trading on Friday. It had originally aimed for $86.3m in proceeds when it first filed last month.
Spun out of Johns Hopkins University in 2011,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.